Description
Riximyo (rituximab) uses: Riximyo is an intravenous medication given to adults to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.
Fact Table |
Formula |
C6416H9874N1688O1987S44 |
License |
US FDA, EMA |
Bioavailability |
N/A (Intravenous administration) |
Legal status |
Prescription only |
Chemical Name |
Rituximab |
Elimination half-life |
18-22 days |
Dosage (Strength) |
100 mg/10 mL, 500 mg/50 mL |
Pregnancy |
Consult a doctor |
Brands |
Rituxan, MabThera, Rixathon, Riximyo, Truxima |
Protein binding |
N/A |
PubChem CID |
50958573 |
MedlinePlus |
a607038 |
ChEBI |
63638 |
ATC code |
L01XC02 |
DrugBank |
DB00073 |
KEGG |
D02993 |
Routes of administration |
Intravenous |
Directions
Your healthcare provider will decide on the right treatment plan for you. A healthcare professional will administer Riximyo intravenous infusion. Your healthcare provider may also give you medications prior to your infusion to help manage side effects.
Talk to your healthcare provider if you have any questions or concerns.
Ingredients
The active ingredient in Riximyo is rituximab.
Contraindications
Patients with any of the following should not receive Riximyo infusion:
- An allergy to any of the ingredients in Riximyo
- Active infections that are severe
- A weak immune system
- Severe heart failure or heart disease (when used for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris)
Cautions
- Before you begin Riximyo treatment, talk to your healthcare provider about:
- All the prescription and over-the-counter medications you take
- Your allergies
- Your current health problems and past medical history
- Your pregnancy or breastfeeding status
- Progressive multifocal leukoencephalopathy can rarely occur.
- Infusion-related reactions that may become severe or fatal can occur.
- Hypersensitivity reactions, including anaphylaxis, can occur.
- Heart problems can occur.
- Abnormal blood cell counts can occur.
- Infections can occur, including hepatitis B reactivation.
- Live vaccines are not recommended while being treated with Riximyo.
Side Effects
Infections, abnormal blood cell counts, infusion-related reactions, nausea, itching, rash, hair loss, fever, chills, weakness, and headache are common side effects associated with Riximyo. However, other side effects may also occur. Immediately inform your healthcare provider of side effects that bother you or won’t go away.
Ask your healthcare provider about Riximyo.
Reference:
Riximyo. European Medicines Agency; 2022.
About Dr. Savannah Muncy (Page Author)
Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14444